Laurus Labs Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Laurus Labs Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Laurus Labs Ltd. from all sources in a single place.

Load latest

Laurus Labs Ltd.

24 Apr 2025

666.60

-0.02%

Company Update

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please see annexed enclosure.

pdf

Laurus Labs Ltd.

24 Apr 2025

666.60

-0.02%

Investor Presentation

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Please see annexed enclosure

pdf

Laurus Labs Ltd.

24 Apr 2025

666.60

-0.02%

Corp. Action

Laurus Labs Ltd - 540222 - Corporate Action-Board approves Dividend

BSE India

Please see annexed enclosure.

pdf

Laurus Labs Ltd.

24 Apr 2025

666.60

-0.02%

Board Meeting

Laurus Labs Ltd - 540222 - Board Meeting Outcome for Board Meeting Outcome - 24.04.2025

BSE India

Please see annexed enclosure.

pdf

Laurus Labs Ltd.

24 Apr 2025

666.60

-0.02%

Result

Laurus Labs Ltd - 540222 - Results - Year Ended March 31, 2025

BSE India

Please see annexed enclosure.

pdf

	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	1778.87	1424.47	1458.20	24.9%	22.0%
Operating Profit Qtr	420.60	285.15	241.49	47.5%	74.2%
Net Profit Qtr	233.67	92.30	75.61	153.2%	209.0%
Earning Per Share Adjusted latest Qtr	4.33	1.71	1.40	153.2%	209.3%

* Consolidated data

Detailed Results

Laurus Labs Ltd.

24 Apr 2025

666.60

-0.02%

Annual Report

Annual report for Laurus Labs Ltd. for FY-2025

None

pdf

Laurus Labs Ltd.

24 Apr 2025

666.60

-0.02%

FDF/CDMO drives earnings; ends FY25 on strong note

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered a second consecutive quarter with betterthan-expected performance, led by healthy traction in the Formulation (FDF)/API segment. Despite softer-than-expected performance in the CDMO business during 4QFY25, the quarterly sales run rate continued its uptrend.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

15 Apr 2025

666.60

-0.02%

Company Update

Laurus Labs Ltd - 540222 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Please see annexed enclosure.

pdf

Laurus Labs Ltd.

11 Apr 2025

666.60

-0.02%

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

Business Standard

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.